此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ST-503的安全性和耐受性研究用于小纤维神经病相关的难治性疼痛

2026年10月30日 更新者:Sangamo Therapeutics

多中心1双盲,随机,假剂量升级研究研究,以确定单剂量鞘内ST-503基因治疗的安全性和耐受性,以减轻特发性小纤维神经病(ISFN)引起的难治性疼痛

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).

研究概览

详细说明

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

Small fiber neuropathy happens when something damages small nerve fibers in your skin, causing symptoms like painful tingling or burning sensations in your hands and feet. Pain originating in the nerves outside of the brain and spinal cord is defined by doctors as neuropathic pain. Scientists have discovered that certain proteins in our bodies called sodium channels are important for communicating pain signals in nerves, specifically, Nav1.7, Nav1.8 and Nav1.9. This first-in-human study will test the use of a type of experimental treatment called "gene therapy." The primary goal is to determine if it is safe and well tolerated. The second goal is to determine if it reduces the level of refractory pain due to SFN disease. The gene will be delivered into your cells using a special delivery tool called a vector.

研究类型

介入性

注册 (估计的)

27

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Scottsdale、Arizona、美国、85260
        • HonorHealth
    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • University of Arkansas for Medical Sciences
    • California
      • La Jolla、California、美国、92093
        • The University of California, San Diego
    • Maryland
      • Baltimore、Maryland、美国、21218
        • Johns Hopkins University
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital
    • New Hampshire
      • Lebanon、New Hampshire、美国、03766
        • Dartmouth Hitchcock Medical Center
    • New York
      • New York、New York、美国、10027
        • Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH)
    • North Carolina
      • Chapel Hill、North Carolina、美国、27514
        • University of North Carolina Medical Center
    • Tennessee
      • Nashville、Tennessee、美国、37235
        • Vanderbilt University
    • Utah
      • Salt Lake City、Utah、美国、84112
        • University of Utah
    • Virginia
      • Richmond、Virginia、美国、23284
        • Virginia Commonwealth University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria

  1. Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) criteria.
  2. Medical record documentation that pain is refractory to 2 of 3 categories of first line medical therapy for at ≥ 6 months prior to screening.
  3. Serum sample negative for pre-existing anti-AAV9 antibodies determined by assay detection limit

Exclusion Criteria

  1. Drug- and alcohol-related:

    1. Persons using opioid analgesics for under 3 months or persons who are not on a stable dose of opioids; if on a stable dose, the dose may decrease over the course of the study but should not be increased.
    2. History of known alcohol abuse, opioid analgesic abuse, or illicit drug abuse within 2 years of Screening.
    3. Positive urine test for drugs of abuse (including opiates, benzodiazepines, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription and investigator approval, at Screening and Day -1.
    4. Use of cannabinoids is not permitted.
  2. Persons with Fabry's disease, with erythromelalgia, with peripheral neuropathies due to alcohol or drug toxicity, or with diagnosed channelopathies

  3. Procedure-related:

    1. Contraindications to LP, general anesthesia or sedation
    2. Any medical disorders that, in the opinion of the Investigator, could interfere with LP including but not limited to evidence for a pressure gradient between supratentorial and infratentorial compartments, Arnold-Chiari malformation, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, increased intracranial pressure, or spine disease or past surgical procedures involving the spine
  4. Infectious disease-related:

    1. Active viral infection or bacterial
    2. A severe infection (e.g., pneumonia, septicemia, central nervous system infections [e.g., meningitis, encephalitis]) within 12 weeks prior to Screening
  5. Hepatic disease- and hepatotoxic medication-related:

    1. Presence of clinically relevant liver disease
    2. Hepatic dysfunction as indicated by one or more of the following: i. Albumin ≤ 3.5 g/dL ii. Total bilirubin > 1.5 x ULN and direct bilirubin ≥0.5 mg/dL iii. Alkaline phosphatase (ALP) > 2 x ULN iv. Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 x ULN
    3. Hepatotoxic medications should be avoided during the study period including acetaminophen exceeding 4 gm/day unless essential to patient's treatment, approved by investigator, and hepatic dysfunction is not identified
    4. Hepatotoxic supplement use during the study period
  6. Cancer-related:

    a. History of cancer, including B-cell cancers, within 5 years of Screening

    i. Exceptions to this exclusion are fully excised non-melanoma skin cancers, non-metastatic prostate cancer, and fully treated ductal carcinoma in situ of the breast, provided subject has been stable for at least 6 months

    b. Previous autologous or allogeneic bone marrow transplant, peripheral stem cell transplant or solid organ transplantation

  7. Previously received gene or cellular therapy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
假比较器:假对照研究

Sham Procedure

实验性的:研究代理

Genomic Medicine

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence and severity of treatment emergent adverse events (TEAEs)
大体时间:12 weeks

To assess safety and tolerability of ST-503 over a 12-week post-dosing observation period.

12 weeks

次要结果测量

结果测量
措施说明
大体时间
Percentage of subjects with pain intensity reduction from baseline at Week 12
大体时间:12 weeks
  • 30% in the weekly average of daily pain intensity measurements performed using the PI-NRS

  • 50% in the weekly average of daily pain intensity measurements performed using the PI-NRS

    • Dose of rescue medication use
    • Frequency of rescue medication use
12 weeks
Percentage of subjects at Week 12
大体时间:12 weeks
  • Categorized as improved on the patient global impression of change (PGIC) assessment
  • With a ≥ 1-point improvement in suicidal ideation in Columbia Suicide Severity Rating Scale (C-SSRS) responses
12 weeks
Columbia Suicide Severity Rating Scale (CSSRS) Rating
大体时间:12 weeks

With a ≥ 1-point decline in suicidal ideation in Columbia Suicide Severity Rating Scale (CSSRS) responses

12 weeks
Overall Pain Intensity Numerical Rating Scale (PI-NRS) score
大体时间:12 Weeks

Participants will rate their pain intensity using an 11-point Numerical Rating Scale (0=no pain and 10=worst possible pain) and record their score in an electronic diary.

12 Weeks
Short Form McGill Pain Questionnaire-2 (SF-MQ-2)
大体时间:12 Weeks

This pain scale was developed to evaluate chronic neuropathic and non-neuropathic pain in adults. It consists of 22 descriptors of pain in 4 parts (continuous, intermittent, neuropathic, and affective pain types) to be rated from 0-10 with 0 indicating no pain and 10 the worst pain ever during the past week.

12 Weeks
Daily Sleep Interference Score (DSIS)
大体时间:12 Weeks

DSIS is assessed on an 11-point NRS, which ranges from 0 (none) to 10 (severe).

12 Weeks
Hospital Anxiety and Depression Scale (HADS)
大体时间:12 Weeks

HADS is a screening tool for anxiety and depression in non-psychiatric clinical populations consisting of 14 items (seven each for anxiety and depression). Higher scores correlate with worse symptoms.

12 Weeks
Rasch-Transformed 13-item SFN Symptoms Inventory Questionnaire
大体时间:12 Weeks

The 13-item SFN-SIQ evaluates changes in physiological functions such as sweating patterns and incontinence using a four-point Likert scale (0 = never present, 1 = sometimes, 2 = often, and 3 = always present) to get a sum of the grading scores attributed to each of the 13 items with a 0 to 39 range. Higher scores correlate with worse symptoms.

12 Weeks
SFN-specific Rasch-built Overall Disability Scale (SFN-RODS)
大体时间:12 Weeks

The 32-item SFN-RODS is a disease-specific interval measure suitable to detect activity limitations and participation restrictions in patients with SFN. The scale ranges from 0 to 64 with higher numbers indicating worse disability.

12 Weeks
36-Item Short Form Health Survey (SF-36) domains and summary scores
大体时间:12 Weeks

This measures quality of life measures such as physical functioning, emotional well-being, energy levels, and social functioning. The range is from 0-100 with higher scores being associated with a better perceived quality of life.

12 Weeks
Pain Catastrophizing Questionnaire (PCS)
大体时间:12 Weeks

PCS has 13 questions related to rumination, magnification and helplessness with values ranging 0 to 4 for a total possible score of 52. The higher the score the more pain catastrophizing is present.

12 Weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Medical Monitor、Sangamo Therapeutics Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月4日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2028年7月1日

研究注册日期

首次提交

2025年4月30日

首先提交符合 QC 标准的

2025年5月12日

首次发布 (实际的)

2025年5月20日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月30日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • ST-503-101

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅